Laboratory and clinical studies on teicoplanin

Yoshitsugu Miyazaki; Yasuhito Higashiyama; Haruko Matsuda; Kohtaro Mitsutake; Yuko Yamashita; Kenichi Tanaka; Masanori Iwamoto; Shigefumi Maesaki; Atsuro Hashimoto; Kazunori Tomono; Hironobu Koga; Shigeru Kohno; Kohei Hara; Chikako Mochida; Kazuyuki Sugawara; Mitsuo Kaku; Takakazu Ohtsubo; Hiroshi Yamada; Yuichi Inoue; Kohichi Watanabe

doi:10.11250/chemotherapy1953.41.Supplement2_190

Laboratory and clinical studies on teicoplanin

Yoshitsugu Miyazaki, Yasuhito Higashiyama, Haruko Matsuda, Kohtaro Mitsutake, Yuko Yamashita, Kenichi Tanaka, Masanori Iwamoto, Shigefumi Maesaki, Atsuro Hashimoto, Kazunori Tomono, Hironobu Koga, Shigeru Kohno, Kohei Hara, Chikako Mochida, Kazuyuki Sugawara, Mitsuo Kaku, Takakazu Ohtsubo, Hiroshi Yamada, Yuichi Inoue, Kohichi Watanabe

MED - Medical Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

A newly developed glycopeptide antibiotic, teicoplanin (TEIC), was evaluated in vitro and in vivo in comparison with imipenem, ceftazidime, ceftizoxime, cefuzonam, piperacillin, KT-3777, cefaclor, cefixime, amoxicillin, vancomycin, cefotiam and minocycline. The results were as follows, 1) Antimicrobial activity : Minimum inhibitory concentrations (MICs) against 180 clinical isolates including 5 different species were determined by the microbroth dilution method. TEIC showed excellent antimicrobial activity against gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA). 2) Clinical efficacy and adverse reactions : 8 patients with infections such as sepsis, pneumonia and pulmonary abscess were treated with TEIC, and the overall efficacy was good in 3 cases, poor in 1 case and unjudged in 4 cases. Fever was observed in 1 case as a side effect of TEIC. Eosinophilia in 1 case and elevation of GOT and GPT in 1 case were also observed as abnormal laboratory findings, however, they were mild and transient, and improved rapidly after the completion of TEIC treatment.

Original language	English
Pages (from-to)	190-195
Number of pages	6
Journal	Chemotherapy
Volume	41
DOIs	https://doi.org/10.11250/chemotherapy1953.41.Supplement2_190
Publication status	Published - 1993

Keywords

MRSA
Teicoplanin
glycopeptide

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology
Drug Discovery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11250/chemotherapy1953.41.Supplement2_190

Cite this

Miyazaki, Y., Higashiyama, Y., Matsuda, H., Mitsutake, K., Yamashita, Y., Tanaka, K., Iwamoto, M., Maesaki, S., Hashimoto, A., Tomono, K., Koga, H., Kohno, S., Hara, K., Mochida, C., Sugawara, K., Kaku, M., Ohtsubo, T., Yamada, H., Inoue, Y., & Watanabe, K. (1993). Laboratory and clinical studies on teicoplanin. Chemotherapy, 41, 190-195. https://doi.org/10.11250/chemotherapy1953.41.Supplement2_190

Miyazaki, Y, Higashiyama, Y, Matsuda, H, Mitsutake, K, Yamashita, Y, Tanaka, K, Iwamoto, M, Maesaki, S, Hashimoto, A, Tomono, K, Koga, H, Kohno, S, Hara, K, Mochida, C, Sugawara, K, Kaku, M, Ohtsubo, T, Yamada, H, Inoue, Y & Watanabe, K 1993, 'Laboratory and clinical studies on teicoplanin', Chemotherapy, vol. 41, pp. 190-195. https://doi.org/10.11250/chemotherapy1953.41.Supplement2_190

@article{f714d4500f904db197e5f3be44616b98,

title = "Laboratory and clinical studies on teicoplanin",

abstract = "A newly developed glycopeptide antibiotic, teicoplanin (TEIC), was evaluated in vitro and in vivo in comparison with imipenem, ceftazidime, ceftizoxime, cefuzonam, piperacillin, KT-3777, cefaclor, cefixime, amoxicillin, vancomycin, cefotiam and minocycline. The results were as follows, 1) Antimicrobial activity : Minimum inhibitory concentrations (MICs) against 180 clinical isolates including 5 different species were determined by the microbroth dilution method. TEIC showed excellent antimicrobial activity against gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA). 2) Clinical efficacy and adverse reactions : 8 patients with infections such as sepsis, pneumonia and pulmonary abscess were treated with TEIC, and the overall efficacy was good in 3 cases, poor in 1 case and unjudged in 4 cases. Fever was observed in 1 case as a side effect of TEIC. Eosinophilia in 1 case and elevation of GOT and GPT in 1 case were also observed as abnormal laboratory findings, however, they were mild and transient, and improved rapidly after the completion of TEIC treatment.",

keywords = "MRSA, Teicoplanin, glycopeptide",

author = "Yoshitsugu Miyazaki and Yasuhito Higashiyama and Haruko Matsuda and Kohtaro Mitsutake and Yuko Yamashita and Kenichi Tanaka and Masanori Iwamoto and Shigefumi Maesaki and Atsuro Hashimoto and Kazunori Tomono and Hironobu Koga and Shigeru Kohno and Kohei Hara and Chikako Mochida and Kazuyuki Sugawara and Mitsuo Kaku and Takakazu Ohtsubo and Hiroshi Yamada and Yuichi Inoue and Kohichi Watanabe",

year = "1993",

doi = "10.11250/chemotherapy1953.41.Supplement2_190",

language = "English",

volume = "41",

pages = "190--195",

journal = "CHEMOTHERAPY",

issn = "0009-3165",

}

TY - JOUR

T1 - Laboratory and clinical studies on teicoplanin

AU - Miyazaki, Yoshitsugu

AU - Higashiyama, Yasuhito

AU - Matsuda, Haruko

AU - Mitsutake, Kohtaro

AU - Yamashita, Yuko

AU - Tanaka, Kenichi

AU - Iwamoto, Masanori

AU - Maesaki, Shigefumi

AU - Hashimoto, Atsuro

AU - Tomono, Kazunori

AU - Koga, Hironobu

AU - Kohno, Shigeru

AU - Hara, Kohei

AU - Mochida, Chikako

AU - Sugawara, Kazuyuki

AU - Kaku, Mitsuo

AU - Ohtsubo, Takakazu

AU - Yamada, Hiroshi

AU - Inoue, Yuichi

AU - Watanabe, Kohichi

PY - 1993

Y1 - 1993

N2 - A newly developed glycopeptide antibiotic, teicoplanin (TEIC), was evaluated in vitro and in vivo in comparison with imipenem, ceftazidime, ceftizoxime, cefuzonam, piperacillin, KT-3777, cefaclor, cefixime, amoxicillin, vancomycin, cefotiam and minocycline. The results were as follows, 1) Antimicrobial activity : Minimum inhibitory concentrations (MICs) against 180 clinical isolates including 5 different species were determined by the microbroth dilution method. TEIC showed excellent antimicrobial activity against gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA). 2) Clinical efficacy and adverse reactions : 8 patients with infections such as sepsis, pneumonia and pulmonary abscess were treated with TEIC, and the overall efficacy was good in 3 cases, poor in 1 case and unjudged in 4 cases. Fever was observed in 1 case as a side effect of TEIC. Eosinophilia in 1 case and elevation of GOT and GPT in 1 case were also observed as abnormal laboratory findings, however, they were mild and transient, and improved rapidly after the completion of TEIC treatment.

AB - A newly developed glycopeptide antibiotic, teicoplanin (TEIC), was evaluated in vitro and in vivo in comparison with imipenem, ceftazidime, ceftizoxime, cefuzonam, piperacillin, KT-3777, cefaclor, cefixime, amoxicillin, vancomycin, cefotiam and minocycline. The results were as follows, 1) Antimicrobial activity : Minimum inhibitory concentrations (MICs) against 180 clinical isolates including 5 different species were determined by the microbroth dilution method. TEIC showed excellent antimicrobial activity against gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA). 2) Clinical efficacy and adverse reactions : 8 patients with infections such as sepsis, pneumonia and pulmonary abscess were treated with TEIC, and the overall efficacy was good in 3 cases, poor in 1 case and unjudged in 4 cases. Fever was observed in 1 case as a side effect of TEIC. Eosinophilia in 1 case and elevation of GOT and GPT in 1 case were also observed as abnormal laboratory findings, however, they were mild and transient, and improved rapidly after the completion of TEIC treatment.

KW - MRSA

KW - Teicoplanin

KW - glycopeptide

UR - http://www.scopus.com/inward/record.url?scp=0027361476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027361476&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.41.Supplement2_190

DO - 10.11250/chemotherapy1953.41.Supplement2_190

M3 - Article

AN - SCOPUS:0027361476

SN - 0009-3165

VL - 41

SP - 190

EP - 195

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

ER -

Laboratory and clinical studies on teicoplanin

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this